MediPharm Labs Corp.

Equities

LABS

CA58504D1006

Pharmaceuticals

Market Closed - Toronto S.E. 03:53:27 2024-03-27 pm EDT 5-day change 1st Jan Change
0.09 CAD -5.26% Intraday chart for MediPharm Labs Corp. +38.46% +38.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5% MT
MediPharm Labs Narrows Q4 Loss, Revenue Grows MT
Transcript : MediPharm Labs Corp., Q4 2023 Earnings Call, Mar 27, 2024
MediPharm Labs Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MediPharm Labs Corp. Brief: Q4 Revenue $9.131 Million; Says Annual Revenue and Adjusted EBITDA Improve by 50% MT
MediPharm Labs Offers Update on German Cannabis Legalization; Up Nearly 6% MT
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023 MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization MT
MediPharm Labs Offers Update on German Cannabis Legalization MT
MediPharm Labs Corp. Brief: Says "Historic change is a significant positive step in removing the stigma related to medical cannabis" MT
MediPharm Labs Corp. Brief: Providing Update on German Cannabis Legalization MT
MediPharm Labs Corp. Says Achieved Pharmaceutical GMP Certification with Brazilian Health Authority MT
MediPharm Labs Corp. Brief: Says Achieved Pharmaceutical GMP Certification with Brazilian Health Authority MT
Transcript : MediPharm Labs Corp., Q3 2023 Earnings Call, Nov 14, 2023
MediPharm Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
MediPharm Labs Corp. Updated On $9 Million Settlement Agreement; All Tilray Shares Sold and Converted to Cash MT
MediPharm Labs Corp. Brief: Updating on $9 Million Settlement Agreement; All Tilray Shares Sold and Converted to Cash MT
Tilray Brands, Inc. acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. for CAD 8.5 million. CI
MediPharm Labs Corp. Says Settled an Outstanding Claim for $9 Million MT
MediPharm Labs Corp. Brief: Says Settled an Outstanding Claim for $9 Million MT
MediPharm Labs Jumps Near 7% As Launches New Products In Australia MT
MediPharm Labs Launches New Products In Australia MT
MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market CI
MediPharm Labs Corp. Brief: Launching new GMP Products to the Australian Medical Cannabis Market MT
Chart MediPharm Labs Corp.
More charts
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.09 CAD
Average target price
0.1 CAD
Spread / Average Target
+11.11%
Consensus
  1. Stock
  2. Equities
  3. Stock MediPharm Labs Corp. - Toronto S.E.
  4. News MediPharm Labs Corp.
  5. MediPharm Labs : Completes New Cannabis Oil Shipment to German Partner